The DOI matches its Crossref record.
Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5‐HT3 receptor antagonist
Abstract
Psychosis, linked to chronic levodopa and other antiparkinsonian drug treatments, is a common and incapacitating complication of advanced Parkinson's disease (PD). The psychosis may be due, in part, to overstimulation of central serotonergic (5-HT) receptors. We treated 16 PD patients who had psychosis of 6 to 60 months' duration with the 5-HT3 receptor antagonist ondansetron (12 to 24 mg daily) in an open-label, short-term (4 to 8 weeks) trial. There was marked to moderate improvement (p < 0.01) in measures of visual hallucinations, paranoid delusions, confusion, and the associated global functional impairment in all but one of the patients, and there was moderate improvement in the Brief Psychiatric Rating Scale and the Nurse's Observation Scale for Inpatient Evaluation; the Mini-Mental State Examination scores remained unaltered. Ondansetron did not cause any worsening in basic PD symptoms or levodopa efficacy and was well tolerated with no major side effects. Our study suggests that pharmacologic blockade of central 5-HT receptors may become a strategy to attenuate PD psychosis without inducing motor deterioration or suppression of antiparkinsonian action of levodopa, and it lends support to the hypothesis that serotonergic mechanisms are pathogenetically important in the emergence of psychosis in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Collerton, D., Perry, E., & McKeith, I. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000130 · Cited by 437
Ondo, W. G., Tintner, R., Dat Voung, K., Lai, D., & Ringholz, G. (2005) · Movement Disorders · doi:10.1002/mds.20474 · Cited by 297
Diederich, N. J., Goetz, C. G., & Stebbins, G. T. (2005) · Movement Disorders · doi:10.1002/mds.20308 · Cited by 290
Metadata
- Authors
- Zoldan, J., Friedberg, G., Livneh, M., & Melamed, E.
- Venue
- Neurology
- Published
- 1995-07
- Volume
- 45
- Issue
- 7
- Pages
- 1305-1308
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1967155455
- Cited by
- 193
- References
- 0
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5‐HT3 receptor antagonist. https://app.cochat.ai/papers/10.1212/wnl.45.7.1305
- The paper
- Zoldan, J., Friedberg, G., Livneh, M., & Melamed, E. (1995). Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5‐HT3 receptor antagonist. Neurology. https://doi.org/10.1212/wnl.45.7.1305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.